Special Issue

New Advances in Tumor Metastasis Angiogenesis-Dependent Processes

Message from the Guest Editors

In 2022, the World Health Organization estimates that cancer is the leading cause of death worldwide. The spreading of tumor cells from the primary tumor to surrounding tissues and distant organs, also called metastasis, constitutes the main cause of cancerassociated morbidity and mortality worldwide. It occurs in a wide range of solid tumors including breast, colorectal, liver, skin cancers, and others, It has been estimated that 90% of cancer deaths are due to metastasis. The cellular and molecular mechanisms behind the angiogenic role in metastatic spreading are still under investigation. Defining them is crucial to highlight novel potential therapeutic opportunities and combinations and overcome therapeutic resistance altogether to increase patient survival. This Special Issue will cover the following topics:

- Angiogenic cellular and molecular mechanisms regulating metastatic spreading and metastasis growth.
- Anti-angiogenic therapies for metastatic spreading and metastasis growth targeting.

Review, research articles, and clinical evaluations are welcome.

Guest Editors

Dr. Jimmy Stalin

Pathology, Department of Oncology, Microbiology and Immunology, Section of Medicine, Faculty of Science and Medicine, University of Fribourg, Chemin du Musée 18, CH-1700 Fribourg, Switzerland

Prof. Dr. Curzio R. Rüegg

Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland

Deadline for manuscript submissions

closed (15 September 2023)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/139328

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

